In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Discover how Teqtivity simplifies IT asset management with user-based pricing, flexible workflows, and clear communication—ideal for modern, cost-conscious IT teams.